Actively Recruiting
Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets
Led by Imperial College London · Updated on 2026-04-14
50
Participants Needed
1
Research Sites
77 weeks
Total Duration
On this page
Sponsors
I
Imperial College London
Lead Sponsor
I
Imperial College Healthcare NHS Trust
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study is to examine exacerbations of chronic obstructive pulmonary disease (COPD) caused by a common cold virus called rhinovirus, to identify new treatments. Exacerbations are flare-ups of respiratory symptoms which are a major cause of ill health in people with COPD, and are most commonly caused by viruses. The main questions the study aims to answer are: * What processes in the body occur in response to rhinovirus infection, and do the differences between people with COPD and healthy volunteers explain why people with COPD develop more severe illness and exacerbations? * Can treatments be identified that target these processes to reduce the severity and frequency of exacerbations in people with COPD? The study will compare eligible participants with COPD to healthy volunteers, and will involve intentionally infecting each participant with rhinovirus in a controlled environment. They will undergo baseline investigations prior to infection including a first bronchoscopy. Post-infection each participant will undergo a range of tests, including a second bronchoscopy, to compare how processes in the body, and especially the lungs, differ between people who do and do not have COPD.
CONDITIONS
Official Title
Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female sex
- Age 40 to 75 years at the time of signing the consent form
- Medical history or clinical diagnosis of COPD for COPD subjects
- Significant smoking history of at least 20 pack years for COPD subjects and smoking controls
- Permitted to currently use, or have history of use of, e-cigarettes/vapes for COPD subjects and smoking controls
- COPD spirometry for COPD subjects: post bronchodilator FEV1 <80% and 60;50% predicted, FEV1/FVC ratio <0.7, and limited b2-agonist reversibility
- History of acute exacerbations of COPD with symptom worsening when catching a cold
- Clinically stable with no COPD exacerbations within 8 weeks prior to enrolment
- Permitted to use short and long-acting bronchodilators including beta agonists and muscarinic antagonist inhalers
- Permitted past history of asthma, allergic rhinitis, seasonal rhinitis not active within 8 weeks prior to enrolment
- Absence of other significant respiratory diseases except COPD, asthma, allergic rhinitis
- Permitted positive skin test for atopy
- No history or diagnosis of COPD for non-smoking and smoking controls
- No significant smoking history (<5 pack years) and no smoking or vaping in last 1 year for non-smoking controls
- Control spirometry for non-smoking controls: FEV1 60;80% predicted, FEV1/FVC ratio 60;0.7
You will not qualify if you...
- Other causes of chronic airflow limitation such as bronchiectasis, bronchiolitis obliterans, bronchus carcinoma, pulmonary fibrosis
- Significant systemic diseases that increase risk or interfere with study outcomes
- Pregnant, planning pregnancy, positive pregnancy test at screening, or nursing within 30 days of treatment
- Use of oral, inhaled or nasal corticosteroids within 8 weeks prior to enrolment
- Use of antibiotics within 8 weeks prior to enrolment
- Use of nasal medications, anti-leukotrienes, or anti-histamines during the study
- Presence of serum rhinovirus-A16 neutralising antibodies above threshold at screening
- Close contact with vulnerable groups such as infants under 6 months, very elderly or infirm, pregnant/breastfeeding women, immunosuppressed patients
- Participation in other clinical studies that pose risk, interfere with outcomes, or create unacceptable visit burden
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Imperial College Healthcare NHS Trust
London, United Kingdom
Actively Recruiting
Research Team
D
Dominic P Wilkins, MBBS
CONTACT
C
Carmen Chan
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here